Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer.
复制标题
DOI：
10.1186/bcr2766
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Schwarzenbach H
中科院分区：
文献类型：
--
作者：
Roth C;Rack B;Müller V;Janni W;Pantel K;Schwarzenbach H
MicroRNA (miR) 是有趣的新诊断靶点，可能为乳腺癌的分子发病机制提供重要见解。在这里，我们首次评估了循环 miR 作为乳腺癌检测和分期生物标志物的可行性和临床实用性。通过 TaqMan MicroRNA 检测，测量了 89 名原发性乳腺癌 (M0，n = 59) 和转移性疾病 (M1，n = 30) 患者以及 29 名健康女性的血清中乳腺癌相关 miR10b、miR34a、miR141 和 miR155 的相对浓度。血清中总RNA（P = 0.0001）和miR155（P = 0.0001）的相对浓度显着区分M0患者与健康女性，而miR10b（P = 0.005）、miR34a（P = 0.001）和miR155（P = 0.008）将M1患者与健康对照区分开来。在乳腺癌患者中，总 RNA (P = 0.0001)、miR10b (P = 0.01)、miR34a (P = 0.003) 和 miR155 (P = 0.002) 水平的变化与明显转移的存在相关。在 M0 队列中，晚期肿瘤阶段（pT3 至 4）患者血液中的总 RNA（P = 0.0001）和 miR34a（P = 0.01）显着高于早期肿瘤阶段（pT1 至 2）患者。这项初步研究提供了第一个证据，证明乳腺癌患者血液中与肿瘤相关的循环 miR 升高，并与肿瘤进展相关。
MicroRNAs (miRs) are interesting new diagnostic targets that may provide important insights into the molecular pathogenesis of breast cancer. Here we evaluated, for the first time, the feasibility and clinical utility of circulating miRs as biomarkers for the detection and staging of breast cancer. The relative concentrations of breast cancer-associated miR10b, miR34a, miR141 and miR155 were measured in the blood serum of 89 patients with primary breast cancer (M0, n = 59) and metastatic disease (M1, n = 30), and 29 healthy women by a TaqMan MicroRNA Assay. The relative concentrations of total RNA (P = 0.0001) and miR155 (P = 0.0001) in serum significantly discriminated M0-patients from healthy women, whereas miR10b (P = 0.005), miR34a (P = 0.001) and miR155 (P = 0.008) discriminated M1-patients from healthy controls. In breast cancer patients, the changes in the levels of total RNA (P = 0.0001), miR10b (P = 0.01), miR34a (P = 0.003) and miR155 (P = 0.002) correlated with the presence of overt metastases. Within the M0-cohort, patients at advanced tumor stages (pT3 to 4) had significantly more total RNA (P = 0.0001) and miR34a (P = 0.01) in their blood than patients at early tumor stages (pT1 to 2). This pilot study provides first evidence that tumor-associated circulating miRs are elevated in the blood of breast cancer patients and associated with tumor progression.
登录
查看更多内容
影响因子：
5.3
作者：
Kong, William;Yang, Hua;Cheng, Jin Q.
通讯作者：
Cheng, Jin Q.
影响因子：
56.9
作者：
Thai, To-Ha;Calado, Dinis Pedro;Rajewsky, Klaus
通讯作者：
Rajewsky, Klaus
影响因子：
11.5
作者：
Willipinski-Stapelfeldt, B;Riethdorf, S;Pantel, K
通讯作者：
Pantel, K
影响因子：
78.8
作者：
Pantel, Klaus;Alix-Panabieres, Catherine;Riethdorf, Sabine
通讯作者：
Riethdorf, Sabine
影响因子：
6.5
作者：
Lawrie, Charles H.;Gal, Shira;Harris, Adrian L.
通讯作者：
Harris, Adrian L.